APONTIS PHARM. AG INH ON news, videos and press releases
For more news please use our advanced search feature.
APONTIS PHARM. AG INH ON - More news...
APONTIS PHARM. AG INH ON - More news...
- EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
- EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
- EQS-News: APONTIS PHARMA expects profitable growth again in 2024
- EQS-News: APONTIS PHARMA successfully completes performance and efficiency improvement program
- EQS-News: APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
- EQS-Adhoc: APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
- EQS-News: APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
- EQS-Adhoc: APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
- EQS-News: APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
- EQS-Adhoc: APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
- EQS-News: APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor
- EQS-Adhoc: APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
- EQS-News: APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023
- EQS-News: APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition year in focusing on Single Pills
- EQS-News: APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development partnership with Zentiva Group for another Single Pill with EU-wide intellectual property rights
- EQS-Adhoc: APONTIS PHARMA AG adjusts forecast for fiscal year 2023
- EQS-News: APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024
- EQS-News: APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio with EU-wide property rights opens up additional revenue potential
- EQS-News: APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations
- EQS-News: APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023
- EQS-News: APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
- EQS-News: APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
- EQS-News: APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
- EQS-News: APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
- DGAP-News: APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill
- DGAP-News: APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
- DGAP-News: APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights
- DGAP-News: APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis
- DGAP-News: APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052
- DGAP-News: APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million
